Bioventus Inc. · NASDAQ:BVS
Bioventus — Canaccord Genuity Global Growth Conference 2024
9 slides from Bioventus's conference presentation, Aug 14, 2024
Slide 1: Bioventus Overview
Bioventus Overview Canaccord Genuity Global Growth Conference August 14, 2024 Mark Singleton Dave Crawford Chief Financial Officer VP IR & Treasurer
Slide 2: Forward-Looking Statements
Innovations For Active Healing Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentati
Slide 3: Strong market leadership position today with significant value creation opportunity ahead
Innovations For Active Healing Strong market leadership position today with significant value creation opportunity ahead Market Leadership Market Opportunity Value Creation Category Leader or Growth Leader 1 $562M Accelerate Revenue Growth Across All Segments Global Revenue Combined with Mid-70s 1 G
Slide 4: Significant progress in addressing challenges and well-positioned to continue improving business execution and performance
Innovations For Active Healing Significant progress in addressing challenges and well-positioned to continue improving business execution and performance 2022 Challenges Current Status Flat Organic Growth Accelerating to Double Digits Profitability Improvement Through Business Profitability and Cost
Slide 5: Accelerating organic growth ahead of market growth
Innovations For Active Healing Accelerating organic growth ahead of market growth Past Headwinds Current Tailwinds Organic Growth 2022 - 2024 • Above market growth in Surgical • Loss of focus on BGS distributors due to Misonix integration Solutions and International region 12.2% • HA price move from
Slide 6: Significant increase in Adjusted EBITDA in 2023 and projected into 2024
Innovations For Active Healing Significant increase in Adjusted EBITDA in 2023 and projected into 2024 Adjusted EBITDA for 2022 – 2024 Increased Adjusted EBITDA by 30% in 2023 and increased by 27% in first half of 2024 105.5 $ millions 88.9 66.3 Generated $10 million of annual savings in 2023 from r
Slide 7: EBITDA growth and debt repayment drive substantial net leverage ratio improvement
Innovations For Active Healing EBITDA growth and debt repayment drive substantial net leverage ratio improvement Net Leverage Ratio1 5.50 Amended credit agreement with bank partners in January 2024 which provides cushion to target metrics through Q3 2025 3.70 Reduced Term Loan and Revolver borrowing
Slide 8: Operating cash flow has turned positive and momentum is building
Innovations For Active Healing Operating cash flow has turned positive and momentum is building Reduced one-time cash costs as acquisition Cash from Operations 2022 - 2024 integration, debt amendment and corporate 27.8 restructuring wind down 15.3 Enhanced accounts receivable collection after rise i
Slide 9: BIOVENTUS: Well-positioned for shareholder value creation
Innovations For Active Healing BIOVENTUS: Well-positioned for shareholder value creation Diversified Portfolio with Current and Future Growth Drivers Accelerating Revenue Starting in 2024 with Peer-leading Gross Margin Expanding Operating Margin, Reducing Debt, and Increasing Cash Flow Substantial O
Bioventus — Canaccord Genuity Global Growth Conference 2024 on 6ix